NCIt definition : An orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1)
and 2 (SGLT2), with potential antihyperglycemic activity. Upon oral administration,
sotagliflozin binds to and blocks both SGLT1 in the gastrointestinal (GI) tract and
SGLT2 in the kidneys, thereby suppressing the absorption of glucose from the GI tract
and the reabsorption of glucose by the proximal tubule into the bloodstream, respectively.
This decreases glucose uptake and enhances the urinary excretion of glucose, which
lowers and/or normalizes blood glucose levels. SGLT1 is the primary transporter responsible
for glucose absorption from the GI tract. SGLT2, a transport protein exclusively expressed
in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption
from tubular fluid.;